BioPharma Drug Discovery
XtalPi Launches XFEP and XMolGen to Transform Drug Discovery with AI and Physics-Based Tools
XtalPi announced the official launch of XFEP and XMolGen, two proprietary software products designed to accelerate and enhance the efficiency of drug disco...
September 25, 2024 | News
Nuance Pharma Expands Bentrio® Nasal Spray Launch in Asia, Files for Mainland China Approval
Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles in Hong Kong and filed request for ...
September 24, 2024 | News
CD Biopharma Receives FDA Clearance for IND Application of CD-001, Paving the Way for Phase I Clinical Trial
CD (Suzhou) Biopharma has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application...
September 23, 2024 | News
Henlius Receives Positive CHMP Opinion for HANSIZHUANG (Serplulimab) as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer in Europe
Shanghai Henlius Biotech, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued ...
September 23, 2024 | News
Axcelead Drug Discovery Partners and Acadia Pharmaceuticals Sign Master Service Agreement to Advance Novel Drug Discovery
Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; hereinafter referred to as “Axcelead DDP”) announced on September 10 tha...
September 20, 2024 | News
Full-Life Technologies Secures $571.5M Licensing Deal with SK Biopharmaceuticals for Anti-Cancer Radiopharmaceutical FL-091
Full-Life Technologies seals $571.5 million agreement with SK Biopharmaceuticals to license and further develop Full-Life's 'FL-091' ra...
September 19, 2024 | News
Singapore Becomes First Southeast Asian Market to Launch BESREMi®️, Setting a New Standard for Rare Disease Care
PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator specializing in haematology and oncology, proudly announces the launch of BES...
September 17, 2024 | News
Senhwa Biosciences' Silmitasertib Receives Rare Pediatric Disease Designation from US FDA for Neuroblastoma
Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious d...
September 13, 2024 | News
NextPoint Therapeutics Introduces NPX372, a Novel T Cell Engager Targeting B7-H7 Axis in Solid Tumors
NextPoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision immuno-oncology and tumor-directed therapeutics targetin...
September 09, 2024 | News
HKBU’s Centre for Chinese Herbal Medicine Drug Development Receives Approval for Clinical Trial of Novel Ulcerative Colitis Drug
Centre for Chinese Herbal Medicine Drug Development (CDD) at Hong Kong Baptist University (HKBU) has achieved a significant milestone in dev...
September 05, 2024 | News
Skyline Therapeutics Secures FDA Orphan Drug Designation for Gene Therapy SKG1108 to Treat Retinitis Pigmentosa
Skyline Therapeutics, an innovation-driven gene therapy company committed to developing unique and novel solutions for rare and severe diseases, announced ...
September 04, 2024 | News
Jacobio Pharma Grants China Rights for KRAS G12C and SHP2 Inhibitors to Shanghai Allist in Landmark Deal
Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that it has granted the China ...
September 02, 2024 | News
European Commission Approves BRAFTOVI® + MEKTOVI® Combo for BRAFV600E-Mutated Advanced NSCLC
European approval is based on results from the Phase II PHAROS trial, which showed a meaningful clinical benefit to BRAFV600E mutated advanced ...
September 02, 2024 | News
Hyundai Bioscience Advances Xafty® as Sole Oral COVID-19 Treatment for High-Risk Patients Ineligible for Paxlovid®
"Xafty® can be the only oral COVID-19 treatment that can be prescribed to high-risk group patients who cannot take Paxlovid®" "While maintaining...
August 29, 2024 | News
Most Read
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Avance Clinical Appoints Jessica Han as Director of Asian Operations, Strengthening Commitment to the Asian Market
- Bristol Myers Squibb Employees Cycle Coast-to-Coast to Raise $1 Million for Cancer Research
- Pfizer Australia Commits $150M to Upgrade Melbourne Facility, Bolstering Global Fight Against Antimicrobial Resistance
- SMi Systems Appoints Dr. Stefan Hamill as Vice President of Strategy to Drive Commercialisation and Growth
- Thermo Fisher Scientific Appoints William Hung as Senior Director and General Manager for Taiwan
- Cytiva Appoints Industry Veteran Pierre-Alain Ruffieux as Chief Operating Officer
News
